Hepatosplenic T-Cell Lymphomas

  • Lohith Gowda
  • Francine FossEmail author
Part of the Cancer Treatment and Research book series (CTAR, volume 176)


Hepatosplenic T-cell lymphoma (HSTL) is a rare variant of extranodal peripheral T-cell lymphomas (PTCL), associated with aggressive disease course and a relentless track record for lethal outcomes. HSTL presents commonly in young men in their third or fourth decade. Of the known causes, immune dysregulation and immunosuppression are the key players in the pathogenesis of HSTL. Clinical manifestation includes hepatosplenomegaly, fevers, and weakness. Bone marrow involvement or organomegaly can cause cytopenias. Anthracycline-based regimens provide modest responses with most individuals dying within a year of diagnosis. Hematopoietic stem cell transplant (HSCT) can be offered to fit and eligible patients to prolong remissions. Disease relapse post chemotherapy has an aggressive phenotype, with limited salvage options available in the setting of declining performance status. Understanding the disease biology further to identify mechanistic-driven drug discovery could overcome the current limitations of existing therapeutic armamentarium.


Hepatosplenic T-cell lymphoma Immunosuppression Stem cell transplantation Genomic landscape 


  1. 1.
    Kadin ME, Kamoun M, Lamberg J (1981) Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. N Engl J Med 304:648–653CrossRefGoogle Scholar
  2. 2.
    Farcet JP, Gaulard P, Marolleau JP et al (1990) Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 75:2213–2219PubMedGoogle Scholar
  3. 3.
    Vose J, Armitage J, Weisenburger D (2008) International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130Google Scholar
  4. 4.
    Cooke CB, Krenacs L, Stetler-Stevenson M et al (1996) Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 88:4265–4274PubMedGoogle Scholar
  5. 5.
    Bucy RP, Chen CL, Cooper MD (1989) Tissue localization and CD8 accessory molecule expression of T gamma delta cells in humans. J Immunol 142:3045–3049PubMedGoogle Scholar
  6. 6.
    Gaulard P, Bourquelot P, Kanavaros P et al (1990) Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol 137:617–628PubMedPubMedCentralGoogle Scholar
  7. 7.
    Picker LJ, Brenner MB, Michie S, Warnke RA (1988) Expression of T cell receptor delta chains in benign and malignant T lineage lymphoproliferations. Am J Pathol 132:401–405PubMedPubMedCentralGoogle Scholar
  8. 8.
    Moser B, Eberl M (2007) Gammadelta T cells: novel initiators of adaptive immunity. Immunol Rev 215:89–102CrossRefGoogle Scholar
  9. 9.
    Adams EJ, Gu S, Luoma AM (2015) Human gamma delta T cells: evolution and ligand recognition. Cell Immunol 296:31–40CrossRefGoogle Scholar
  10. 10.
    Koizumi H, Liu CC, Zheng LM et al (1991) Expression of perforin and serine esterases by human gamma/delta T cells. J Exp Med 173:499–502CrossRefGoogle Scholar
  11. 11.
    He Y, Wu K, Hu Y et al (2014) Gammadelta T cell and other immune cells crosstalk in cellular immunity. J Immunol Res 2014:960252PubMedPubMedCentralGoogle Scholar
  12. 12.
    Tripodo C, Iannitto E, Florena AM et al (2009) Gamma-delta T-cell lymphomas. Nat Rev Clin Oncol 6:707–717CrossRefGoogle Scholar
  13. 13.
    Kotlyar DS, Osterman MT, Diamond RH et al (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9(36–41):e31Google Scholar
  14. 14.
    Gaulard P, Belhadj K, Reyes F (2003) Gammadelta T-cell lymphomas. Semin Hematol 40:233–243CrossRefGoogle Scholar
  15. 15.
    Miyazaki K, Yamaguchi M, Imai H et al (2009) Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 113:1071–1074CrossRefGoogle Scholar
  16. 16.
    Travert M, Huang Y, de Leval L et al (2012) Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 119:5795–5806CrossRefGoogle Scholar
  17. 17.
    Nicolae A, Xi L, Pittaluga S et al (2014) Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia 28:2244–2248CrossRefGoogle Scholar
  18. 18.
    McKinney M, Moffitt AB, Gaulard P et al (2017) The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov 7:369–379CrossRefGoogle Scholar
  19. 19.
    Ross CW, Schnitzer B, Sheldon S, Braun DK, Hanson CA (1994) Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen. Am J Clin Pathol 102:310–315CrossRefGoogle Scholar
  20. 20.
    Kanavaros P, Lescs MC, Briere J et al (1993) Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81:2688–2695PubMedGoogle Scholar
  21. 21.
    Ohshima K, Haraoka S, Harada N et al (2000) Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology 36:127–135CrossRefGoogle Scholar
  22. 22.
    Belhadj K, Reyes F, Farcet JP et al (2003) Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102:4261–4269CrossRefGoogle Scholar
  23. 23.
    Weidmann E (2000) Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14:991–997CrossRefGoogle Scholar
  24. 24.
    Berti E, Cerri A, Cavicchini S et al (1991) Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol 96:718–723CrossRefGoogle Scholar
  25. 25.
    Ralfkiaer E, Wollf-Sneedorff A, Thomsen K, Geisler C, Vejlsgaard GL (1992) T-cell receptor gamma delta-positive peripheral T-cell lymphomas presenting in the skin: a clinical, histological and immunophenotypic study. Exp Dermatol 1:31–36CrossRefGoogle Scholar
  26. 26.
    Wlodarska I, Martin-Garcia N, Achten R et al (2002) Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosom Cancer 33:243–251CrossRefGoogle Scholar
  27. 27.
    Yabe M, Medeiros LJ, Tang G et al (2016) Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. Am J Surg Pathol 40:676–688CrossRefGoogle Scholar
  28. 28.
    Gumbs AA, Zain J, Neylon E, MacGregor-Cortelli B, Patterson M, O’Connor OA (2009) Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia. Ann Surg Oncol 16:2014–2017CrossRefGoogle Scholar
  29. 29.
    Weledji EP (2014) Benefits and risks of splenectomy. Int J Surg 12:113–119CrossRefGoogle Scholar
  30. 30.
    Takamatsu Y, Suzumiya J, Utsunomiya A et al (2010) THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol 84:391–397CrossRefGoogle Scholar
  31. 31.
    Voss MH, Lunning MA, Maragulia JC et al (2013) Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 13:8–14CrossRefGoogle Scholar
  32. 32.
    Falchook GS, Vega F, Dang NH et al (2009) Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 20:1080–1085CrossRefGoogle Scholar
  33. 33.
    Jaeger G, Bauer F, Brezinschek R, Beham-Schmid C, Mannhalter C, Neumeister P (2008) Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 19:1025–1026CrossRefGoogle Scholar
  34. 34.
    Mittal S, Milner BJ, Johnston PW, Culligan DJ (2006) A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 76:531–534CrossRefGoogle Scholar
  35. 35.
    Moleti ML, Testi AM, Giona F et al (2006) Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone. Leuk Lymphoma 47:333–336CrossRefGoogle Scholar
  36. 36.
    Tey SK, Marlton PV, Hawley CM, Norris D, Gill DS (2008) Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 83:330–333CrossRefGoogle Scholar
  37. 37.
    Tanase A, Schmitz N, Stein H et al (2015) Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT lymphoma working party. Leukemia 29:686–688CrossRefGoogle Scholar
  38. 38.
    Rashidi A, Cashen AF (2015) Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J 5:e318CrossRefGoogle Scholar
  39. 39.
    Opavsky R, Wang SH, Trikha P et al (2007) CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet 3:1757–1769CrossRefGoogle Scholar
  40. 40.
    Kucuk C, Jiang B, Hu X et al (2015) Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun 6:6025CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hematology and Bone Marrow TransplantationYale University School of MedicineNew HavenUSA

Personalised recommendations